SEGMENT REPORTING - Schedule of Segment Revenue and Significant Segment Expenses (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Mar. 31, 2026 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| REVENUE: | ||||||
| Total segment revenue | $ 0 | $ 18,168 | $ 367 | $ 229,414 | ||
| LESS: | ||||||
| Research and development | (22,331) | (43,503) | (38,428) | (92,212) | ||
| Other external costs | (5,377) | (8,542) | (11,576) | (17,405) | ||
| Net income (loss) | (28,710) | $ (23,708) | (30,696) | $ 148,451 | (52,418) | 117,755 |
| Reportable Segment | ||||||
| REVENUE: | ||||||
| Total segment revenue | 0 | 18,168 | 367 | 229,414 | ||
| LESS: | ||||||
| Compensation costs (excluding stock based compensation) | (7,725) | (13,842) | (15,915) | (27,619) | ||
| Other segment items | (3,618) | (178) | (8,121) | (13,336) | ||
| Net income (loss) | (28,710) | (30,696) | (52,418) | 117,755 | ||
| Reportable Segment | Rinvatercept program expenses | ||||||
| LESS: | ||||||
| Research and development | (4,101) | (1,431) | (6,751) | (2,948) | ||
| Reportable Segment | Elritercept program expenses | ||||||
| LESS: | ||||||
| Research and development | (14) | (15,636) | (17) | (34,531) | ||
| Reportable Segment | Cibotercept program expenses | ||||||
| LESS: | ||||||
| Research and development | (267) | (4,059) | 57 | (9,967) | ||
| Reportable Segment | Preclinical & development expenses | ||||||
| LESS: | ||||||
| Research and development | (6,111) | (1,981) | (8,117) | (3,725) | ||
| Reportable Segment | Other external costs | ||||||
| LESS: | ||||||
| Other external costs | $ (6,874) | $ (11,737) | $ (13,921) | $ (19,533) | ||
| X | ||||||||||
- Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Other employee benefit expense includes, but is not limited to, service component of net periodic benefit cost for defined benefit plan. Excludes compensation cost in cost of good and service sold. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|